AI and ML Enhance ECG Interpretation

By Michael Awood

September 22, 2023

We’ve shown how AI and ML help diagnose and manage heart problems. New research has recently shown that a new ML model can improve ECG data interpretation, reducing misdiagnosis and optimizing patient monitoring data.

A further step is to look at monitoring and early disease detection while patients are being monitored within the home space. This is something our recent insight article has touched on.

By using traditional signal processing and ML, this model can overcome challenges caused by noisy data. They evaluated it using real-world single-lead ECG data from acutely ill patients receiving care at home as part of a ‘home hospital’ program. The model showed excellent performance, with a sensitivity of 98%, a specificity of 100%, an accuracy of 98%, a positive predictive value of 100%, and a negative predictive value of 93%.

It was effective in interpreting telemetry feeds for acutely ill patients. The current systems can detect atrial fibrillation with 92% accuracy and paroxysmal supraventricular tachycardia with 93% accuracy. However, the new ML algorithm could enhance arrhythmia identification.

The ML model can monitor chronically ill patients during medication changes or diagnose hidden arrhythmia. It could form the basis of a system that consistently monitors cardiac health through arrhythmia detection.

The study evaluated a single-lead ECG hybrid ML algorithm using data from acutely ill patients within a ‘home hospital’ programme. It shows the potential of AI and ML to enhance healthcare delivery and patient outcomes, particularly in cardiology. Investigating the impact of long-term arrhythmia burden on health outcomes is crucial for future research.

Reference url

Recent Posts

Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...
Ravulizumab aHUS Reimbursement Reassessment: Navigating New Evidence and Treatment Impact

By HEOR Staff Writer

September 15, 2025

Zorginstituut Nederland is reassessing ravulizumab aHUS reimbursement for treating atypical hemolytic uremic syndrome (aHUS) - a rare immune system disorder. The drug was previously rejected in 2021 due to insufficient scientific evidence. The medication is administered via infusion and targets p...
Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in Clinics

By João L. Carapinha

September 10, 2025

Unproven fertility treatments—a term referring to add-on procedures without robust clinical evidence—have come under renewed scrutiny in the UK. Many prospective parents want to know: Why are unproven fertility treatments being discouraged, and what does this mean for fertility clinic choices...